News Release：2024 | Eisai Co., Ltd.
WebMar 28, 2024 · eisai’s initiatives for developing new medicines for neglected tropical diseases and malaria and commitment for funding to the 3rd phase of global health innovative technology fund activities. may 24, 2023. eisai delivers new data and highlights continued progress of oncology portfolio and pipeline at asco 2023. may 22, 2023
FDA Approves LEQEMBI™ (lecanemab-irmb) Under the ... - Eisai …
WebJan 7, 2023 · LEQEMBI will be available during or before the week of January 23, 2023. Eisai announced the U.S. pricing and rationale for LEQEMBI today. Eisai serves as the lead of LEQEMBI development and regulatory submissions globally with both Eisai and Biogen co-commercializing and co-promoting the product and Eisai having final decision-making …
EISAI TO PRESENT DATA ON LECANEMAB AND OTHER …
WebFeb 29, 2024 · Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced today the company will present the latest findings on lecanemab (generic name, U.S. brand name: LEQEMBI ® ), Eisai’s anti-amyloid beta (Aβ) protofibril* antibody for the treatment of Alzheimer’s disease (AD), at the 2024 International Conference on Alzheimer ...
EISAI PRESENTS FULL RESULTS OF LECANEMAB PHASE 3 …
WebNovember 30, 2022. TOKYO and CAMBRIDGE, Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, "Biogen") announced today that the results from Eisai’s large global Phase 3 confirmatory Clarity AD clinical study of ...
LECANEMAB CONFIRMATORY PHASE 3 CLARITY AD STUDY MET ... - Eisai …
WebSep 28, 2022 · eisai's news release lecanemab confirmatory phase 3 clarity ad study met primary endpoint, showing highly statistically significant reduction of clinical decline in large global clinical study of 1,795 participants with early alzheimer’s disease is posted.
News Release：2021 | Eisai Co., Ltd.
WebDec 16, 2021 · New Phase 3 Data Show Positive Correlation Between ADUHELM™ Treatment Effect on Biomarkers and Reduction in Clinical Decline in Alzheimer’s Disease. November 12, 2021. EISAI PRESENTS NEW ANALYSIS OF LECANEMAB CLINICAL EFFICACY RESULTS FROM PHASE 2B STUDY AT CLINICAL TRIALS ON …
EISAI AND BIOGEN INC. ANNOUNCE U.S. FDA GRANTS …
WebJune 24, 2021. Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Michel Vounatsos, “Biogen”) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for lecanemab (BAN2401), an ...
REVENUE OF LEQEMBI® (PRELIMINARY BASIS) | News Release：2024 | Eisai …
Web4 days ago · April 24, 2024. Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced today that the global revenue of the anti-amyloid-beta protofibril antibody LEQEMBI ® in the fourth quarter of fiscal year 2023 (January 1, 2024 – March 31, 2024) was JPY 2.83 billion (pre-audit basis), which was approximately 2.7 times higher than ...
News Release：2022 | Eisai Co., Ltd.
WebDecember 1, 2022. EISAI TO PRESENT PRECLINICAL AND CLINICAL RESEARCH ON ERIBULIN AT THE 2022 SAN ANTONIO BREAST CANCER SYMPOSIUM. November 30, 2022. EISAI PRESENTS FULL RESULTS OF LECANEMAB PHASE 3 CONFIRMATORY CLARITY AD STUDY FOR EARLY ALZHEIMER’S DISEASE AT CLINICAL TRIALS ON …
Eisai Newsroom - Press Releases
WebTOKYO, Oct. 15, 2023 /PRNewswire/ -- Eisai Co. Ltd (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today that the company will present new data from the phase 3 Clarity AD study for its Alzheimer's disease (AD) treatment LEQEMBI ® (lecanemab-irmb) 100 mg/mL injection for intravenous use and new data on the subcutaneous formulation ...
Skip to content